These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 37182741)

  • 1. Hypomethylation of the dopamine transporter (DAT) gene promoter is associated with hyperphagia-related behavior in Prader-Willi syndrome: A case-control study.
    Wieting J; Jahn K; Eberlein CK; Bleich S; Frieling H; Deest M
    Behav Brain Res; 2023 Jul; 450():114494. PubMed ID: 37182741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alteration of serum leptin and LEP/LEPR promoter methylation in Prader-Willi syndrome.
    Wieting J; Jahn K; Buchholz V; Lichtinghagen R; Deest-Gaubatz S; Bleich S; Eberlein CK; Deest M; Frieling H
    Psychoneuroendocrinology; 2022 Sep; 143():105857. PubMed ID: 35803048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct promoter regions of the oxytocin receptor gene are hypomethylated in Prader-Willi syndrome and in Prader-Willi syndrome associated psychosis.
    Heseding HM; Jahn K; Eberlein CK; Wieting J; Maier HB; Proskynitopoulos PJ; Glahn A; Bleich S; Frieling H; Deest M
    Transl Psychiatry; 2022 Jun; 12(1):246. PubMed ID: 35688807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Behavioral changes in patients with Prader-Willi syndrome receiving diazoxide choline extended-release tablets compared to the PATH for PWS natural history study.
    Strong TV; Miller JL; McCandless SE; Gevers E; Yanovski JA; Matesevac L; Bohonowych J; Ballal S; Yen K; Hirano P; Cowen NM; Bhatnagar A
    J Neurodev Disord; 2024 Apr; 16(1):22. PubMed ID: 38671361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Prader-Willi syndrome Profile: validation of a new measure of behavioral and emotional problems in Prader-Willi syndrome.
    Dykens EM; Roof E; Hunt-Hawkins H
    Orphanet J Rare Dis; 2024 Feb; 19(1):83. PubMed ID: 38395848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calorie seeking, but not hedonic response, contributes to hyperphagia in a mouse model for Prader-Willi syndrome.
    Davies JR; Humby T; Dwyer DM; Garfield AS; Furby H; Wilkinson LS; Wells T; Isles AR
    Eur J Neurosci; 2015 Aug; 42(4):2105-13. PubMed ID: 26040449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Trials in Prader-Willi Syndrome: A Review.
    Mahmoud R; Kimonis V; Butler MG
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypomethylation of monoamine oxidase A promoter/exon 1 region is associated with temper outbursts in Prader-Willi syndrome.
    Deest M; Buchholz V; Jahn K; Eberlein C; Bleich S; Frieling H
    J Psychiatr Res; 2022 May; 149():359-366. PubMed ID: 34782122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential DNA methylation in iPSC-derived dopaminergic neurons: a step forward on the role of SNORD116 microdeletion in the pathophysiology of addictive behavior in Prader-Willi syndrome.
    Salles J; Eddiry S; Amri S; Galindo M; Lacassagne E; George S; Mialhe X; Lhuillier É; Franchitto N; Jeanneteau F; Gennero I; Salles JP; Tauber M
    Mol Psychiatry; 2024 Sep; 29(9):2742-2752. PubMed ID: 38561465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and relationship between hyperphagia, anxiety, behavioral challenges and caregiver burden in Prader-Willi syndrome.
    Kayadjanian N; Vrana-Diaz C; Bohonowych J; Strong TV; Morin J; Potvin D; Schwartz L
    PLoS One; 2021; 16(3):e0248739. PubMed ID: 33765021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disentangling ingestive behavior-related phenotypes in Prader-Willi syndrome: Integrating information from nonclinical studies and clinical trials to better understand the pathophysiology of hyperphagia and obesity.
    Wevrick R
    Physiol Behav; 2020 May; 219():112864. PubMed ID: 32156555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changeability of the fully methylated status of the 15q11.2 region in induced pluripotent stem cells derived from a patient with Prader-Willi syndrome.
    Okuno H; Nakabayashi K; Abe K; Ando T; Sanosaka T; Kohyama J; Akamatsu W; Ohyama M; Takahashi T; Kosaki K; Okano H
    Congenit Anom (Kyoto); 2017 Jul; 57(4):96-103. PubMed ID: 28004416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysregulated adipose tissue expansion and impaired adipogenesis in Prader-Willi syndrome children before obesity-onset.
    Chao Y; Gao L; Wang X; Cai Y; Shu Y; Zou X; Qin Y; Hu C; Dai Y; Zhu M; Shen Z; Zou C
    Metabolism; 2022 Nov; 136():155295. PubMed ID: 36007622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome.
    Salehi P; Hsu I; Azen CG; Mittelman SD; Geffner ME; Jeandron D
    Pediatr Obes; 2017 Jun; 12(3):221-228. PubMed ID: 27071367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Appetite hormones and the transition to hyperphagia in children with Prader-Willi syndrome.
    Goldstone AP; Holland AJ; Butler JV; Whittington JE
    Int J Obes (Lond); 2012 Dec; 36(12):1564-70. PubMed ID: 22270375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial.
    Allas S; Caixàs A; Poitou C; Coupaye M; Thuilleaux D; Lorenzini F; Diene G; Crinò A; Illouz F; Grugni G; Potvin D; Bocchini S; Delale T; Abribat T; Tauber M
    PLoS One; 2018; 13(1):e0190849. PubMed ID: 29320575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prader-Willi syndrome: From genetics to behaviour, with special focus on appetite treatments.
    Griggs JL; Sinnayah P; Mathai ML
    Neurosci Biobehav Rev; 2015 Dec; 59():155-72. PubMed ID: 26475993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of Hyperphagia Questionnaire for Clinical Trials (HQ-CT) scores in typically developing individuals and those with Prader-Willi syndrome.
    Matesevac L; Vrana-Diaz CJ; Bohonowych JE; Schwartz L; Strong TV
    Sci Rep; 2023 Nov; 13(1):20573. PubMed ID: 37996659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcranial direct current stimulation reduces food-craving and measures of hyperphagia behavior in participants with Prader-Willi syndrome.
    Bravo GL; Poje AB; Perissinotti I; Marcondes BF; Villamar MF; Manzardo AM; Luque L; LePage JF; Stafford D; Fregni F; Butler MG
    Am J Med Genet B Neuropsychiatr Genet; 2016 Mar; 171B(2):266-75. PubMed ID: 26590516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal Carbetocin Reduces Hyperphagia, Anxiousness, and Distress in Prader-Willi Syndrome: CARE-PWS Phase 3 Trial.
    Roof E; Deal CL; McCandless SE; Cowan RL; Miller JL; Hamilton JK; Roeder ER; McCormack SE; Roshan Lal TR; Abdul-Latif HD; Haqq AM; Obrynba KS; Torchen LC; Vidmar AP; Viskochil DH; Chanoine JP; Lam CKL; Pierce MJ; Williams LL; Bird LM; Butler MG; Jensen DE; Myers SE; Oatman OJ; Baskaran C; Chalmers LJ; Fu C; Alos N; McLean SD; Shah A; Whitman BY; Blumenstein BA; Leonard SF; Ernest JP; Cormier JW; Cotter SP; Ryman DC
    J Clin Endocrinol Metab; 2023 Jun; 108(7):1696-1708. PubMed ID: 36633570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.